Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04329949
Terminated
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Site #058, Detroit, Michigan
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04729608
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
NCT03416153
Active Not Recruiting
This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2023
Locations: University of Michigan Hospital, Ann Arbor, Michigan +1 locations
Conditions: Oropharynx Cancer
Register for Updates
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02272790
Completed
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Gender:
FEMALE
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2023
Locations: Research Site, Detroit, Michigan
Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Register for Updates
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03611556
Completed
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
09/08/2023
Locations: Research Site, Ann Arbor, Michigan
Conditions: Carcinoma, Metastatic Pancreatic Adenocarcinoma
Register for Updates
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390
Completed
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Bixby Medical Center, Adrian, Michigan +32 locations
Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Register for Updates
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT03840915
Completed
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2023
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
NCT00003518
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory metastatic germ cell tumors that have not responded to surgery or chemotherapy.
Gender:
ALL
Ages:
Between 15 years and 120 years
Trial Updated:
06/21/2023
Locations: CCOP - Kalamazoo, Kalamazoo, Michigan
Conditions: Ovarian Cancer, Testicular Germ Cell Tumor
Register for Updates
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00062010
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Giving interferon alfa and isotretinoin together with paclitaxel may reduce resistance to the drug and allow the tumor cells to be killed. PURPOSE: This phase II trial is studying how well giving interferon alfa and isotretinoin together with paclitaxel works in treating patients with recurrent small... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Borgess Medical Center, Kalamazoo, Michigan +3 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
NCT00003237
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of paclitaxel and cisplatin, given after surgery in treating patients with cancer of the esophagus or stomach.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: CCOP - Ann Arbor Regional, Ann Arbor, Michigan
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
NCT00003592
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate or paclitaxel is more effective in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of methotrexate with that of paclitaxel in treating patients who have advanced head and neck cancer that cannot be treated with cisplatin.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/21/2023
Locations: CCOP - Kalamazoo, Kalamazoo, Michigan
Conditions: Head and Neck Cancer
Register for Updates
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
NCT00003298
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells. E7296 was conducted to study neoadjuvant chemotherapy and postoperative chemoradiation therapy in patients diagnosed with high-risk gastric cancer using a new neoadjuvant regimen: paclitaxel plus cisplatin. It was hypothesized that t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: CCOP - Ann Arbor Regional, Ann Arbor, Michigan +1 locations
Conditions: Gastric Cancer
Register for Updates